Lori Mann Bruce, Ph.D., MSU John Ball, Ph.D., Naval Surface Warfare Center Matthew Lee, MSU
Bruce D. Clark, Ph.D.
1
For over 30 years, Dr. Bruce Clark has been a notable leader and advocate in the biopharmaceutical and biotech space, strategically guiding companies through new territory while ensuring corporate goals are achieved. Dr. Clark joined Medicago as Chief Executive Officer (CEO) in March 2017. Prior to this, he served on Medicago’s Board of Directors where he acquired a deep understanding of the company. Dr. Clark’s broad experience in bringing new products to international markets includes the management of commercial operations, regulatory issues, and quality control. Dr. Clark spent many years as the head of regulatory and scientific affairs for companies such as Apotex Canada, Sanofi Synthelabo Canada, GlaxoSmithKline, was CEO of Medexus Inc. Most recently as Vice President of Regulatory and Scientific Affairs of Philip Morris International, Dr. Clark focused on the development and regulatory approvals of modified risk nicotine delivery technologies. He has been extensively involved with both European and US generic pharmaceutical associations related to the issues of biosimilars and complex therapeutics. Dr. Clark is co-author of the EGA Handbook on Biosimilar Medicines published by the European Generic Medicines Association and co-author of the Canadian Handbook on Second Entry Biologics published by the Canadian Generic Pharmaceutical Association. He completed his studies in molecular biology and biochemistry at the University of Toronto, where he received his PhD in 1987. Bruce D. Clark, Ph.D. President and Chief Executive Officer
Transcript of Bruce D. Clark, Ph.D.
For over 30 years, Dr. Bruce Clark has been a notable leader and advocate in the biopharmaceutical and biotech space, strategically guiding companies through new territory while ensuring corporate goals are achieved.
Dr. Clark joined Medicago as Chief Executive Officer (CEO) in March 2017. Prior to this, he served on Medicago’s Board of Directors where he acquired a deep understanding of the company. Dr. Clark’s broad experience in bringing new products to international markets includes the management of commercial operations, regulatory issues, and quality control.
Dr. Clark spent many years as the head of regulatory and scientific affairs for companies such as Apotex Canada, Sanofi Synthelabo Canada, GlaxoSmithKline, was CEO of Medexus Inc. Most recently as Vice President of Regulatory and Scientific Affairs of Philip Morris International, Dr. Clark focused on the development and regulatory approvals of modified risk nicotine delivery technologies. He has been extensively involved with both European and US generic pharmaceutical associations related to the issues of biosimilars and complex therapeutics.
Dr. Clark is co-author of the EGA Handbook on Biosimilar Medicines published by the European Generic Medicines Association and co-author of the Canadian Handbook on Second Entry Biologics published by the Canadian Generic Pharmaceutical Association. He completed his studies in molecular biology and biochemistry at the University of Toronto, where he received his PhD in 1987.
Bruce D. Clark, Ph.D.President and Chief Executive Officer
